ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis
International Immunopharmacology · 2026-09 · 185 · 117006
DOI: 10.1016/j.intimp.2026.117006 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-09. Verfasst von Sichen Di und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China.; Urologic Cancer Institute, To…. Hauptthemen laut MEDLINE: Sunitinib, Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Kidney Neoplasms. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Anhui Provincial Department of Education, Tongji University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200000, China.
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200082, China.
- Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200000, China.. Electroni…
- Department of Urology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.. Electronic address: 3288993092@qq.com.
Förderung
- Science and Technology Commission of Shanghai Municipality
- Anhui Provincial Department of Education
- Tongji University
- China Postdoctoral Science Foundation
- National Key Clinical Specialty Discipline Construction Program of China
- National Natural Science Foundation of China
Zitieren
APA
Di, S., Liu, J., Gu, Z., Jin, C., Zhang, J., Li, K., Liu, Y., Chen, H., Yang, W., Chen, W., Zhang, W., Mao, S., Hao, Y., Zhang, H., Zhu, X., & Yao, X. (2026). ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis. International Immunopharmacology, 185, 117006. https://doi.org/10.1016/j.intimp.2026.117006
Vancouver
Di S, Liu J, Gu Z, Jin C, Zhang J, Li K, et al. ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis. International Immunopharmacology. 2026;185:117006. doi:10.1016/j.intimp.2026.117006
BibTeX
@article{Di2026,
author = {Di, Sichen and Liu, Ji and Gu, Zhuoran and Jin, Chengqi and Zhang, Junfeng and Li, Keqiang and Liu, Yongqiang and Chen, Haotian and Yang, Wei and Chen, Wenjin and Zhang, Wentao and Mao, Shiyu and Hao, Yajuan and Zhang, Haimin and Zhu, Xiaojun and Yao, Xudong},
title = {ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis},
journal = {International Immunopharmacology},
year = {2026},
volume = {185},
pages = {117006},
doi = {10.1016/j.intimp.2026.117006}
}
EUVIMED